EP0966305A1 - Agents de contraste contenant deux types de microbulles remplies de gaz - Google Patents

Agents de contraste contenant deux types de microbulles remplies de gaz

Info

Publication number
EP0966305A1
EP0966305A1 EP98900940A EP98900940A EP0966305A1 EP 0966305 A1 EP0966305 A1 EP 0966305A1 EP 98900940 A EP98900940 A EP 98900940A EP 98900940 A EP98900940 A EP 98900940A EP 0966305 A1 EP0966305 A1 EP 0966305A1
Authority
EP
European Patent Office
Prior art keywords
gas
preparation
types
microparticle
phospholipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP98900940A
Other languages
German (de)
English (en)
Inventor
Jonny Nycomed Imaging AS STENSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
Nycomed Imaging AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging AS filed Critical Nycomed Imaging AS
Publication of EP0966305A1 publication Critical patent/EP0966305A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric

Definitions

  • This invention relates to ultrasound imaging, more particularly to novel contrast agent compositions and preparations comprising at least two types of gas- containing microparticles and to their preparation and use .
  • ultrasound imaging comprises a potentially valuable diagnostic tool, for example in studies of the vascular system, particularly in cardiography, and of tissue microvasculature .
  • contrast agents has been proposed to enhance the acoustic images so obtained, including suspensions of solid particles, emulsified liquid droplets, gas microbubbles and encapsulated gases or liquids.
  • gas-containing and gas-generating systems has attracted particular interest, since the low density and ease of compressibility of gas present or generated in such systems ensure particularly efficient backscatter of ultrasound.
  • porous gas-containing microparticles or as encapsulated gas microbubbles for example using encapsulating materials such as proteins, polymers or film-forming surfactants such as phospholipids .
  • encapsulating materials such as proteins, polymers or film-forming surfactants such as phospholipids .
  • thick encapsulating shells reduce the compressibility and thus the echogenicity of the microbubbles.
  • certain biocompatible fluorocarbons may be used in the form of free gas microbubbles by virtue of their persistence relative to air in aqueous media such as blood.
  • Contrast agents comprising encapsulated or otherwise stabilised dispersions of substantially water-insoluble fluorinated gases have also been proposed - see, for example, the disclosure of O-A-9501187 regarding protein microspheres containing water-insoluble gases such as perfluoropropane and the description of BR1 , a phospholipid-stabilised dispersion of sulphur hexafluoride- filled microbubbles, in Investigative Radiology 30 ( 8 ) , pp. 451-457.
  • contrast agents tend to exhibit a higher echogenic response and lower attenuation than contrast agents having thicker and/or more rigid encapsulating shells, they do in consequence suffer the disadvantage that they have relatively low resistance to high acoustic pressure, for example such as may be encountered in the near field in close proximity to the ultrasound transducer. Imaging at diagnostically useful ultrasound intensities may therefore lead to substantial destruction of the contrast agent in the near field. It has been proposed to overcome this problem by imaging at low acoustic field strengths or by using intermittent ultrasound pulses, for example triggered by every tenth, twentieth or thirtieth cardiac cycle. However, this may prevent continuous imaging with good opacification in the near field and/or give rise to unacceptable signal to noise ratios in the far field remote from the transducer.
  • the present invention is based, inter alia, on the finding that such disadvantages may be mitigated or overcome by use of contrast agents comprising two or more types of gas-containing microparticles which differ in their resistance to ultrasound energy, i.e. in their susceptibility to ultrasonic pressure.
  • contrast agents comprising two or more types of gas-containing microparticles which differ in their resistance to ultrasound energy, i.e. in their susceptibility to ultrasonic pressure.
  • microparticle types having relatively low susceptibility to ultrasonic pressure will provide a response to high acoustic energy in the near field where microparticle types with relatively high susceptibility will tend to be inactivated through destruction.
  • the more highly susceptible microparticle types will, however, be effective in the lower acoustic energy environment of the far field, where lower susceptibility microparticle types will tend to exhibit little interaction.
  • a combined preparation for simultaneous, separate or sequential use as an ultrasound contrast agent comprising at least two different types of gas-containing microparticles, said microparticle types differing in their susceptibility to ultrasonic pressure.
  • a method of generating enhanced images of a human or non-human animal subject which comprises the steps of administering a contrast agent preparation as defined above to said subject and generating an ultrasound image of at least a part of said subject.
  • the differing susceptibility to ultrasonic pressure of the microparticle types may result from physical and/or chemical differences.
  • microparticle types which differ only in size, for example having a bimodal size distribution, in order to achieve the desired difference in susceptibility to ultrasonic pressure.
  • different encapsulating or other stabilising systems will be employed, for example comprising a first microparticle type which has relatively soft encapsulating shells and therefore has relatively high susceptibility to ultrasonic pressure and a second microparticle type which has relatively hard encapsulating or otherwise stabilising material, e.g. in shell or matrix form, and therefore has relatively low susceptibility to ultrasonic pressure.
  • the different microparticle types may be selected from any appropriate gas -containing microparticulate ultrasound contrast agents.
  • Representative examples of such contrast agents include microbubbles of gas stabilised (e.g. at least partially encapsulated) by a coalescence-resistant surface membrane (for example gelatin, e.g. as described in WO-A-8002365) , a filmogenic protein (for example an albumin such as human serum albumin, e.g.
  • WO-A-4718433 US-A- 4774958, US-A-4844882 , EP-A-0359246 , WO-A- 9112823 , WO-A- 9205806, WO-A-9217213 , WO-A-9406477 or WO-A-9501187)
  • a polymer material for example a synthetic biodegradable polymer as described in EP-A-0398935 , an elastic interfacial synthetic polymer membrane as described in EP-A-0458745 , a microparticulate biodegradable polyaldehyde as described in EP-A-0441468 , a microparticulate N-dicarboxylic acid derivative of a polyamino acid - polycyclic imide as described in EP-A- 0458079, or a biodegradable polymer as described in WO- A-9317718 or WO-A-9607434 ) , a non-polymeric and non- polymer
  • gas-containing microparticulate contrast agents include gas-containing solid systems, for example microparticles (especially aggregates of microparticles) having gas contained therewithin or otherwise associated therewith (for example being adsorbed on the surface thereof and/or contained within voids, cavities or pores therein, e.g. as described in EP-A-0122624, EP-A-0123235 , EP-A- 0365467 , WO-A- 9221382 , WO-A-9300930, WO-A-9313802 , WO-A-9313808 or WO-A- 9313809) .
  • gas-containing solid systems for example microparticles (especially aggregates of microparticles) having gas contained therewithin or otherwise associated therewith (for example being adsorbed on the surface thereof and/or contained within voids, cavities or pores therein, e.g. as described in EP-A-0122624, EP-A-0123235 , EP-A- 0365467 , WO-A- 9
  • microparticulate contrast agents may derive directly from the contained/associated gas and/or from gas (e.g. microbubbles) liberated from the solid material (e.g. upon dissolution of the microparticulate structure) .
  • gas e.g. microbubbles
  • Gas-containing microparticles preferably have an initial average size not exceeding 10 ⁇ m (e.g. of 7 ⁇ m or less) in order to permit their free passage through the pulmonary system following administration, e.g. by intravenous injection.
  • phospholipid-containing contrast agents are employed in accordance with the invention, e.g. in the form of gas microbubbles stabilised by monolayers, bilayers or multiple layers of one or more phospholipids
  • useful phospholipids include lecithins (i.e.
  • phosphatidylcholines for example natural lecithins such as egg yolk lecithin or soya bean lecithin and synthetic or semisynthetic lecithins such as dimyristoylphosphatidylcholine , dipalmitoylphosphatidylcholine or distearoylphosphatidylcholine; phosphatidic acids; phosphatidylethanolamines ; phosphatidylserines ; phosphatidylglycerols ; phosphatidylinositols ; cardiolipins ,- sphingomyelins ; fluorinated analogues of any of the foregoing; mixtures of any of the foregoing and mixtures with other lipids such as cholesterol.
  • natural lecithins such as egg yolk lecithin or soya bean lecithin
  • synthetic or semisynthetic lecithins such as dimyristoylphosphatidylcholine ,
  • the fatty acyl groups of such phospholipids will typically each contain about 14-22 carbon atoms, for example as in palmitoyl and stearoyl groups .
  • Lyso forms of such phospholipids are useful in accordance with the invention, the term "lyso" denoting phospholipids containing only one fatty acyl groups, this preferably being ester-linked to the 1-position carbon atom of the glyceryl moiety.
  • Such lyso forms may advantageously be used in admixture with phospholipids containing two fatty acyl groups .
  • Phospholipid shells will in general tend to be relatively flexible, giving rise to microparticles with a relatively high susceptibility to ultrasonic pressure.
  • microparticles comprising relatively hard and inflexible encapsulating shells
  • gas- containing polymer microparticles wherein the polymer is a biodegradable polymer containing units of formula (I)
  • microparticles comprise biodegradable polymers consisting of repeating units of formula (II)
  • Contrast agents comprising gas microbubbles encapsulated by denatured and/or crosslinked protein (e.g. human serum albumin) shells, for example as described in WO-A-9217213 or WO-A-9406477, may also be useful examples of microparticles with relatively hard encapsulating shells.
  • denatured and/or crosslinked protein e.g. human serum albumin
  • gas-containing microparticles which may be useful in contrast agents according to the invention include carbohydrates (for example hexoses such as glucose, fructose or galactose; disaccharides such as sucrose, lactose or maltose; pentoses such as arabinose, xylose or ribose; - , ⁇ - and ⁇ -cyclodextrins ; polysaccharides such as starch, hydroxyethyl starch, amylose, amylopectin, glycogen, inulin, pulullan, dextran, carboxymethyl dextran, dextran phosphate, ketodextran, aminoethyldextran, alginates, chitin, chitosan, hyaluronic acid or heparin; and sugar alcohols, including alditols such as mannitol or sorbitol) , inorganic salts (e.g.
  • X-ray contrast agents e.g. any of the commercially available carboxylic acid and non- ionic amide contrast agents typically containing at least one 2 , 4 , 6-triiodophenyl group having substituents such as carboxyl, carbamoyl , N-alkylcarbamoyl , N- hydroxyalkylcarbamoyl , acylamino, N-alkylacylamino or acylaminomethyl at the 3- and/or 5 -positions, as in metrizoic acid, diatrizoic acid, iothalamic acid, ioxaglic acid, iohexol , iopentol, iopamidol, iodixanol, iopromide, metrizamide, iodipamide, meglumine iodipamide, meglumine ace
  • any biocompatible gas may be present in the microparticles, the term "gas" as used herein including any substances (including mixtures) substantially or completely in gaseous (including vapour) form at the normal human body temperature of 37°C.
  • the gas may thus, for example, comprise air; nitrogen; oxygen; carbon dioxide; hydrogen; an inert gas such as helium, argon, xenon or krypton; a sulphur ' fluoride such as sulphur hexafluoride, disulphur decafluoride or trifluoromethylsulphur pentafluoride; selenium hexafluoride; an optionally halogenated silane such as methylsilane or dimethylsilane; a low molecular weight hydrocarbon (e.g.
  • an alkane such as methane, ethane, a propane, a butane or a pentane, a cycloalkane such as cyclopropane, cyclobutane or cyclopentane, an alkene such as ethylene, propene, propadiene or a butene, or an alkyne such as acetylene or propyne; an ether such as dimethyl ether; a ketone; an ester; a halogenated low molecular weight hydrocarbon (e.g. containing up to 7 carbon atoms); or a mixture of any of the foregoing.
  • an alkane such as methane, ethane, a propane, a butane or a pentane
  • a cycloalkane such as cyclopropane, cyclobutane or cyclopentane
  • an alkene such as ethylene, propene, propadiene or a butene
  • biocompatible halogenated hydrocarbon gases may, for example, be selected from bromochlorodifluoromethane, chlorodifluoromethane , dichlorodifluoromethane , bromotrifluoromethane , chlorotrifluoromethane , chloropentafluoroethane , dichlorotetrafluoroethane , chlorotrifluoroethylene, fluoroethylene, ethylfluoride, 1, l-difluoroethane and perfluorocarbons, e.g.
  • perfluoroalkanes such as perfluoromethane, perfluoroethane, perfluoropropanes, perfluorobutanes (e.g. perfluoro-n-butane, optionally in admixture with other isomers such as perfluoro-iso-butane) , perfluoropentanes, perfluorohexanes and perfluoroheptanes; perfluoroalkenes such as perfluoropropene, perfluorobutenes (e.g.
  • perfluorobut-2- ene and perfluorobutadiene; perfluoroalkynes such as perfluorobut-2-yne ; and perfluorocycloalkanes such as perfluorocyclobutane , perfluoromethylcyclobutane , perfluorodimethylcyclobutanes , perfluorotrimethyl - cyclobutanes, perfluorocyclopentane, perfluoromethyl- cyclopentane, perfluorodimethylcyclopentanes, perfluorocyclohexane, perfluoromethylcyclohexane and perfluorocycloheptane .
  • halogenated gases include methyl chloride, fluorinated (e.g. perfluorinated) ketones such as perfluoroacetone and fluorinated (e.g. perfluorinated) ethers such as perfluorodiethyl ether.
  • perfluorinated gases for example sulphur hexafluoride and perfluorocarbons such as perfluoropropane, perfluorobutanes and perfluoropentanes, may be particularly advantageous in view of the recognised high stability in the bloodstream of microbubbles containing such gases .
  • the same or different gases may be employed in the different types of microparticles.
  • Contrast agent compositions and preparations in accordance with the invention may, for example, be prepared by appropriately admixing the different microparticle types.
  • the microparticles and/or precursor forms thereof may be mixed in the dry state to give a product which may be formulated for administration by admixture with an appropriate aqueous carrier liquid such as sterile water for injection, or one or more of the microparticle types may be suspended or otherwise generated in an aqueous carrier liquid prior to such mixing.
  • Aqueous preparations obtained in accordance with this latter embodiment may be used directly as contrast agents in accordance with the invention or may if desired be dried, for example by lyophilisation, to yield a storage-stable dried reconstitutable composition according to the invention.
  • Phospholipid-stabilised microbubble suspensions for use in the above process may, for example, be prepared by generating a dispersion of gas microbubbles in an aqueous medium containing the phospholipid. This may, for example, be effected by subjecting the phospholipid- containing aqueous medium to any appropriate emulsion- generating technique, for example sonication, shaking, high pressure homogenisation, high speed stirring or high shear mixing, e.g. using a rotor-stator homogeniser, in the presence of the selected gas.
  • any appropriate emulsion- generating technique for example sonication, shaking, high pressure homogenisation, high speed stirring or high shear mixing, e.g. using a rotor-stator homogeniser, in the presence of the selected gas.
  • the aqueous medium may, if desired, contain additives which serve as viscosity enhancers and/or as solubility aids for the lipid, such as alcohols or polyols, e.g. glycerol and/or propylene glycol .
  • the gas employed in the emulsification step need not be that desired in the final product . Thus most of this gas content may be removed during any subsequent lyophilisation step and residual gas may be removed by evacuation of the dried product, to which an atmosphere or overpressure of the desired end product gas may then be applied.
  • the emulsification gas may therefore be selected purely to optimise the emulsification process parameters, without regard to end product considerations.
  • Emulsification in the presence of a sulphur fluoride such as sulphur hexafluoride or a fluorinated low molecular weight hydrocarbon gas such as a perfluoroalkane or perfluorocycloalkane, preferably containing 4 or 5 carbon atoms, may be particularly advantageous in terms of ultimately yielding end products with consistent and narrowly distributed microbubble sizes.
  • the emulsification is conveniently effected at about ambient temperature, e.g. at ca . 25 ⁇ 10°C. It may be necessary initially to heat the aqueous medium to facilitate hydration and thus dispersion of the lipid and then allow it to equilibrate to ambient temperature prior to emulsification.
  • the resulting microbubble suspension may advantageously be subjected to one or more washing steps in order to separate and remove additives such as viscosity enhancers and solubility aids, as well as unwanted material such as non-gas-containing colloidal particles and undersized and/or oversized microbubbles. Such washing may be effected in per se known manner, the microbubbles being separated using techniques such as flotation or centrifugation. In this way size- fractionated microbubble dispersions may be prepared wherein at least 90% of the microbubbles have sizes within a 2 ⁇ m range, e.g. having a volume mean diameter within the range 2-5 ⁇ m.
  • Any lyophilisation step may advantageously be conducted in the presence of one or more cryoprotective and/or lyoprotective and/or bulking agents, such agent (s) advantageously being added after any washing steps, prior to lyophilisation.
  • cryoprotective and/or lyoprotective and/or bulking agents such agent (s) advantageously being added after any washing steps, prior to lyophilisation.
  • Such agents include alcohols (e.g. aliphatic alcohols such as t-butanol) , polyols such as glycerol, aminoacids such as glycine, carbohydrates (e.g. sugars such as sucrose, mannitol, trehalose, glucose, lactose and cyclodextrins, or polysaccharides such as dextran) and polyglycols such as polyethylene glycol , the use of physiologically well- tolerated sugars such as sucrose (e.g. in an amount such as to render the product isotonic or somewhat hypertonic) being preferred.
  • alcohols e.g. aliphatic alcohols such as t-butanol
  • polyols such as glycerol
  • aminoacids such as glycine
  • carbohydrates e.g. sugars such as sucrose, mannitol, trehalose, glucose, lactose and cyclodextrins, or polysacc
  • the mixed product may advantageously be filled into sealable vials prior to lyophilisation so as to give vials each containing an appropriate amount, e.g. a single dosage unit, of lyophilised dried product for reconstitution into an injectable form.
  • an appropriate amount e.g. a single dosage unit
  • the vials may be sealed with an appropriate closure.
  • the lyophilised dried product may be reconstituted by addition of an appropriate injectable carrier liquid such as sterile pyrogen-free water or saline for injection.
  • an appropriate injectable carrier liquid such as sterile pyrogen-free water or saline for injection.
  • the dried product is contained in a vial this is conveniently sealed with a septum through which the carrier liquid may be injected using a syringe. It may be advantageous to mix or gently shake the product following reconstitution; no more than gentle hand-shaking may be required to give reproducible products with consistent microbubble size.
  • the following non-limitative Example serves to illustrate the invention.
  • hydrogenated egg phosphatidylserine 500.4 mg hydrogenated egg phosphatidylserine was added to 100 ml water containing 5.4% (w/w) of a mixture of propylene glycol and glycerol (3:10 w/w). The mixture was shaken and heated to 80 °C for five minutes, allowed to cool to room temperature, shaken again and left standing overnight prior to use .
  • the solution was homogenised at 23000 rpm for 10 minutes, keeping the rotor stator mixing shaft such that the openings were slightly above the surface of the liquid.
  • a white coloured creamy dispersion was obtained, which was transferred to a sealable container and flushed with perfluoro-n-butane .
  • the dispersion was then transferred to a separating funnel and centrifuged at 12000 rpm for 30 minutes, yielding a creamy layer of bubbles at the top and a turbid infranatant .
  • the infranatant was removed and replaced with water.
  • the centrifugation was then repeated twice, but now at 12000 rpm for 15 minutes. After the last centrifugation, the supernatant was replaced by 10 % (w/w) sucrose.
  • Gas-containing polymer microparticles prepared in accordance with any of Examples 3 (a) - (r) of WO-A-9607434 are added to vials containing the lyophilised product from Example 1(a) above, whereafter water for injection is added and the vials are gently hand-shaken for several seconds to give a contrast agent formulation according to the invention.
  • water for injection is added to vials containing the lyophilised product from Example 1 (a) above and the vials are gently hand-shaken to give microbubble dispersions to which the gas-containing polymer microparticles according to any of Examples 3 (a) - (r) of WO-A-9607434 are added, either in dry form or as a dispersion in water for injection.
  • the resulting mixture may be used directly as a contrast agent formulation in accordance with the invention or may be lyophilised to give a storage-stable dried product for subsequent reconstitution with an aqueous carrier such as water for injection.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Acoustics & Sound (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

L'invention concerne des agents de contraste contenant deux ou plusieurs types de microparticules remplies de gaz qui diffèrent quant à leur sensibilité à la pression ultrasonore. Les types de microparticules qui ont une sensibilité à la pression ultrasonore relativement faible réagissent à une énergie acoustique élevée dans le champ proche tandis que les types de microparticules de sensibilité relativement élevée tendent à être inactivés par destruction dans les mêmes conditions. Les types de microparticules de sensibilité plus élevée sont efficaces dans l'environnement inférieur de l'énergie acoustique du champ éloigné, les types de microparticules de sensibilité plus faible tendent à montrer une faible interaction dans les mêmes conditions.
EP98900940A 1997-01-22 1998-01-22 Agents de contraste contenant deux types de microbulles remplies de gaz Ceased EP0966305A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9701237 1997-01-22
GBGB9701237.1A GB9701237D0 (en) 1997-01-22 1997-01-22 Improvements in or relating to contrast agents
PCT/GB1998/000189 WO1998032468A1 (fr) 1997-01-22 1998-01-22 Agents de contraste contenant deux types de microbulles remplies de gaz

Publications (1)

Publication Number Publication Date
EP0966305A1 true EP0966305A1 (fr) 1999-12-29

Family

ID=10806374

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98900940A Ceased EP0966305A1 (fr) 1997-01-22 1998-01-22 Agents de contraste contenant deux types de microbulles remplies de gaz

Country Status (8)

Country Link
EP (1) EP0966305A1 (fr)
JP (1) JP2001508454A (fr)
CN (1) CN1244131A (fr)
AU (1) AU5674098A (fr)
CA (1) CA2278750A1 (fr)
GB (1) GB9701237D0 (fr)
NO (1) NO993438D0 (fr)
WO (1) WO1998032468A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013916A2 (fr) * 1997-09-18 1999-03-25 Nycomed Imaging As Procedes et compositions pour l'imagerie medicale
US9364569B2 (en) 2003-02-04 2016-06-14 Bracco Suisse S.A. Ultrasound contrast agents and process for the preparation thereof
WO2005063305A1 (fr) 2003-12-22 2005-07-14 Bracco Research Sa Systeme de microvesicule remplie de gaz pour l'imagerie de contraste
EP1784228B1 (fr) * 2004-08-18 2016-10-05 Bracco Suisse SA Composition à base de microvésicules remplis de gaz pour l'imagerie de contraste
CN102112176B (zh) * 2008-07-23 2015-08-12 皇家飞利浦电子股份有限公司 超声介导的药物递送
WO2010036964A2 (fr) 2008-09-26 2010-04-01 Ambrx Inc. Polypeptides d'érythropoïétine animale modifiés et leurs utilisations
CN109529033A (zh) * 2018-07-09 2019-03-29 彭盛 一种稳定的载氧微泡及其制备方法和应用
CN113521317B (zh) * 2021-07-01 2023-03-31 中国科学院深圳先进技术研究院 一种双靶向肿瘤的超声分子复合成像方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
DE4100470A1 (de) * 1991-01-09 1992-07-16 Byk Gulden Lomberg Chem Fab Echokontrastmittel
JP3559849B2 (ja) * 1993-07-30 2004-09-02 アイエムシーオーアール ファーマシューティカル カンパニー 超音波技術のための安定化された微小気泡組成物
GB9417941D0 (en) * 1994-09-06 1994-10-26 Nycomed Imaging As Improvements in or relating to contrast agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9832468A1 *

Also Published As

Publication number Publication date
GB9701237D0 (en) 1997-03-12
CN1244131A (zh) 2000-02-09
WO1998032468A1 (fr) 1998-07-30
NO993438L (no) 1999-07-13
CA2278750A1 (fr) 1998-07-30
JP2001508454A (ja) 2001-06-26
NO993438D0 (no) 1999-07-13
AU5674098A (en) 1998-08-18

Similar Documents

Publication Publication Date Title
AU726503B2 (en) Improvements in or relating to contrast agents
EP1590006B1 (fr) Agents de contraste pour ultrasons et procede pour leur elaboration
US7892522B2 (en) Contrast agents
AU722735B2 (en) Thermally stabilized contrast agent
JPH11508871A (ja) 脂質および安定化用物質の新規な組成物
US6054118A (en) Contrast agents comprising two types of gas-containing microparticles
US6217850B1 (en) Method of making lyophilized microbubble compositions useful as contrast agents
WO1998032468A1 (fr) Agents de contraste contenant deux types de microbulles remplies de gaz
EP1007103A2 (fr) Ameliorations relatives aux milieux de contraste
AU784367B2 (en) Improvements in or relating to contrast agents
NO318875B1 (no) Ultralydkontrastmiddel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990707

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19990707;LT PAYMENT 19990707;LV PAYMENT 19990707;MK PAYMENT 19990707;RO PAYMENT 19990707;SI PAYMENT 19990707

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AMERSHAM HEALTH AS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GE HEALTHCARE AS

17Q First examination report despatched

Effective date: 20070221

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20080613